ERBB2 and breast carcinoma: Although trastuzumab and T-DM1 have shown remarkable benefits in HER2+ breast cancer patients, disease resistance and intolerable toxic reactions to these drugs will invariably develop; thus, novel therapeutic approaches are needed.